证券代码: 300957 证券简称:贝泰妮 公告编号:2023-056 1、云南贝泰妮生物科技集团股份有限公司（以下简称"公司"）于2023年8月 30日召开第二届董事会第十次会议和第二届监事会第九次会议，审议通过了《关于 回购公司股份方案的议案》。本次回购股份方案经出席第二届董事会第十次会议的 董事人数超过三分之二审议通过，且独立董事已对本次回购事项发表了同意的独立 意见。根据相关法律法规及《公司章程》规定，本次回购股份方案属于董事会审批权 限，无需提交股东大会审议。 2、回购方案主要内容：自公司董事会审议通过本次回购股份方案之日起不超过 12个月，公司使用自有资金通过集中竞价交易方式回购公司发行的人民币普通股（A 股）股票，用于实施股权激励计划或员工持股计划。本次回购的资金总额不低于人民 币10,000万元（含），且不超过人民币20,000万元（含）。本次回购股份的价格不超 过130元/股（含），按照本次回购金额下限人民币10,000万元测算，回购数量约为 76.9231万股，回购股份比例约占公司总股本的0.1816%；按照本次回购金额上限人民 币20,000万元测算，回购数量约为153.8461万股，回 ...

证券代码：300957 证券简称：贝泰妮 公告编号：2023-057 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 云南贝泰妮生物科技集团股份有限公司（以下简称"公司"）于2023年8月30日 召开第二届董事会第十次会议、第二届监事会第九次会议审议通过了《关于回购公 司股份方案的议案》，公司将以集中竞价交易方式回购公司股份，回购的股份将全 部用于实施股权激励计划或员工持股计划。具体内容详见公司于2023年8月30日披露 在巨潮资讯网的《第二届董事会第十次会议决议公告》（公告编号：2023-052）、 《第二届监事会第九次会议决议公告》（公告编号：2023-053）及《关于回购公司 股份方案的公告》（公告编号：2023-051）等公告。 注：以上股东的持股数量为合并普通账户和融资融券信用账户后的持股数量总数。 二、公司前十大无限售条件股东持股情况 | 序 | 股东名称 | 持股数量（股） | 占无限售流通 | | --- | --- | --- | --- | | 号 | | | 股本比例（%） | | 1 | 天津红杉聚业股权投资合伙企业（有限合伙） | ...

证券代码: 300957 证券简称:贝泰妮 公告编号:2023-051 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚 假记载、误导性陈述或者重大遗漏。 云南贝泰妮生物科技集团股份有限公司（以下简称"公司"）拟以集中竞价交 易方式回购公司股份，回购的股份将全部用于实施股权激励计划或员工持股计划。 1、回购股份的价格区间：不超过人民币130元/股（含）； 2、回购股份的数量及占公司总股本的比例：按照本次回购金额下限人民币 10,000万元，回购价格上限人民币130元/股进行测算，回购数量约为76.9231万股，回 购股份比例约占公司总股本的0.1816%；按照本次回购金额上限人民币20,000万元， 回购价格上限人民币130元/股进行测算，回购数量约为153.8461万股，回购股份比例 约占公司总股本的0.3632%。具体回购股份的数量以回购期满或终止回购时实际回购 的股份数量为准。 3、回购股份的资金总额：不低于人民币10,000万元（含），不超过人民币20,000 万元（含）； 4、回购资金来源：自有资金； 5、回购期限：自公司董事会审议通过回购方案之日起12个月内。 6、相关风险提示： ...

的独立意见 我们作为云南贝泰妮生物科技集团股份有限公司（以下简称"公司"）的独 立董事，本着客观、公正、审慎的原则，根据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司独立董事规则》《深圳证券交易所创业板股 票上市规则》等相关法律、法规和规范性文件以及《公司章程》、公司《独立 董事工作制度》的相关规定，对公司第二届董事会第十次会议审议的关于回购 公司股份方案相关事项发表独立意见如下： 1、公司本次回购股份符合《公司法》《证券法》《深圳证券交易所上市公 司自律监管指引第9号——回购股份》《深圳证券交易所创业板股票上市规则》 等法律法规、规范性文件和《公司章程》的有关规定，审议该事项的董事会表决 程序合法、合规。 2、公司本次回购的股份拟用于实施股权激励计划或员工持股计划，有利于 进一步完善公司长效激励机制，充分调动公司管理人员和核心骨干的积极性，有 利于增强投资者的信心，促进公司长期稳定健康发展。 3、本次回购股份的资金来自公司自有资金，回购价格合理公允。本次回购 股份的实施不会对公司经营、财务、债务履行能力和未来发展等产生重大影响， 不会导致公司控制权发生变化，不存在损害公司及全体股东尤其是中小股 ...

证券代码：300957 证券简称：贝泰妮 公告编号：2023-052 公司独立董事对此议案发表了同意的独立意见。 表决结果：同意票9票，反对票0票，弃权票0票。 特此公告。 云南贝泰妮生物科技集团股份有限公司（以下简称"公司"）第二届董事 会第十次会议于2023年8月30日上午以现场及通讯会议方式举行，现场会议地点 为上海市长宁区金钟路968号天会2号楼公司会议室。本次会议已经全体董事一 致同意豁免会议提前通知期限，会议通知以邮件方式向全体董事送达。本次会 议应出席董事9人，实际出席董事9人，其中现场出席董事3名，通讯出席董事6 名，通讯出席董事为周逵先生、高绍阳先生、周薇女士、李志伟先生、李宁先 生、汪鳌先生，无委托出席董事。公司监事、高级管理人员列席了会议。本次 会议的召开符合《公司法》及《公司章程》的规定。本次会议由董事长GUO ZHENYU（郭振宇）先生主持，与会董事审议并表决通过了如下决议： 一、审议通过《关于回购公司股份方案的议案》。 基于对公司未来发展的信心和对公司价值的认可，为有效维护广大股东利 益，增强投资者信心，同时完善公司长效激励机制，充分调动公司员工的积极 性，有效地将股东利益、公司利 ...

本公司及监事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 云南贝泰妮生物科技集团股份有限公司（以下简称"公司"）第二届监事 会第九次会议于2023年8月30日以现场会议方式在公司会议室举行，现场会议地 点为云南省昆明市高新区科医路 53 号公司会议室。本次会议已经全体监事一致 同意豁免会议提前通知期限，会议通知以邮件方式向全体监事送达。本次会议 应出席监事3人，实际出席监事3人，公司副总经理、财务总监、董事会秘书王 龙先生列席会议。本次会议的召开符合《公司法》及《公司章程》的规定。本 次会议由监事会主席余仕汝先生主持，全体监事审议并表决通过了如下决议： 一、审议通过《关于回购公司股份方案的议案》。 证券代码：300957 证券简称：贝泰妮 公告编号：2023-053 具体内容请见公司同日刊登在巨潮资讯网的《云南贝泰妮生物科技集团股 份有限公司关于回购公司股份方案的公告》。 表决结果：同意票3票、反对票0票、弃权票0票。 特此公告。 云南贝泰妮生物科技集团股份有限公司监事会 2023年8月30日 经核查，公司监事会认为本次回购股份方案不会对公司经营、财务和未来 发展产生 ...

Financial Performance - The company reported a total revenue of 1.2 billion CNY for the first half of 2023, representing a year-on-year increase of 15%[1]. - The company has set a revenue guidance of 2.5 billion CNY for the full year 2023, which reflects a growth target of 10%[1]. - The company expects a revenue growth guidance of 10-15% for the second half of 2023, driven by new product launches and market expansion strategies[9]. - The company's operating revenue for the first half of 2023 was ¥2,367,742,613.94, representing a 15.52% increase compared to ¥2,049,698,508.11 in the same period last year[14]. - The net profit attributable to shareholders was ¥450,012,214.05, up 13.91% from ¥395,043,194.70 year-on-year[14]. - The net cash flow from operating activities increased by 35.02% to ¥284,985,036.70, compared to ¥211,063,345.93 in the same period last year[14]. - The company reported a revenue of RMB 1.2 billion for the first half of 2023, representing a year-on-year increase of 15%[9]. - The company's operating revenue for the first half of 2023 reached RMB 236,774.26 million, representing a year-on-year increase of approximately 15.52%[42]. User Growth and Market Expansion - User data indicates a growth in active users by 20% compared to the same period last year, reaching 5 million active users[1]. - The company is expanding its market presence in Southeast Asia, with plans to open 50 new retail locations by the end of 2023[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by the end of 2024[9]. - The company is focusing on market expansion and new brand development as part of its strategy[105]. Research and Development - Research and development expenses increased by 25% year-on-year, totaling 150 million CNY, to support new technology initiatives[1]. - Investment in R&D increased by 25% year-on-year, focusing on innovative skincare products and advanced biotechnology[9]. - The company employs over 400 R&D personnel across various disciplines, with core technology sales accounting for over 95% of its main business revenue[63]. - The company has established a research institute focusing on innovative raw material development and collaborates with universities and research institutions[32]. - The company has developed a brand matrix with 19 categories and 48 product lines, focusing on sensitive skin care products under the "Winona" brand[61]. Product Development and Innovation - New product launches contributed to 30% of total sales in the first half of 2023, highlighting the success of recent innovations[1]. - A new product line featuring eco-friendly packaging is set to launch in Q3 2023, aiming to capture the growing demand for sustainable beauty products[9]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a focus on companies in the health and wellness sector[9]. - The company launched a new brand "AOXMED" with its first store opening in Beijing in January 2023[38]. Sustainability and Social Responsibility - The management emphasizes a commitment to sustainability and social responsibility in its operational strategies moving forward[1]. - The company has initiated a "bottle recycling" program in 2023, aiming to process used packaging into reusable raw materials, thereby reducing waste and promoting sustainability[114]. - The company invested over RMB 6.58 million in public welfare projects during the reporting period, benefiting more than 12,600 people through various initiatives[121]. - The company has aligned its biodiversity protection efforts with the COP15 framework, committing to 23 action goals to fulfill its corporate responsibility[122]. Financial Management and Investments - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[1]. - The company has committed to a share buyback program of up to 100 million CNY to stabilize stock prices[127]. - The company has obtained ISO14001 environmental management system certification, ensuring compliance with environmental regulations and effective management of noise, wastewater, and waste gas emissions[111]. - The company has not conducted any asset or equity acquisitions or sales during the reporting period[135]. Risks and Challenges - The company faces potential risks related to regulatory changes in the e-commerce sector, which are detailed in the risk management section of the report[1]. - The company faces risks from intensified competition in the cosmetics industry, particularly from international brands increasing their online marketing efforts[96]. - To mitigate risks, the company plans to enhance its strategic adjustments and improve its operational management capabilities[100]. Corporate Governance - The company reported a 74.86% investor participation rate at the 2022 annual general meeting held on May 17, 2023[103]. - The company did not experience any major litigation or arbitration matters during the reporting period[133]. - The company confirmed the integrity status of itself and its controlling shareholders[134]. - The company has not disclosed any new product developments or technological advancements in the current report[145].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan for the first half of 2023, representing a year-on-year growth of 25%[4]. - The company reported a revenue of RMB 1.2 billion for the first half of 2023, representing a year-on-year increase of 15%[9]. - The company achieved a revenue of RMB 236,774.26 million in the first half of 2023, representing a year-on-year increase of approximately 15.52%[42]. - Main business revenue was RMB 235,788.81 million, accounting for 99.58% of total revenue, with a year-on-year growth of 15.56%[43]. - The company reported a net profit attributable to shareholders was ¥450,012,214.05, up 13.91% from ¥395,043,194.70 year-on-year[14]. - The net profit for the first half of 2023 was ¥462,167,072.61, representing a growth of 15.2% from ¥401,182,678.13 in the first half of 2022[164]. - The company reported a net profit margin of 12% for the first half of 2023, an increase from 10% in the same period last year[126]. User Growth and Market Expansion - User data showed a growth in active users, reaching 5 million, which is an increase of 15% compared to the previous year[4]. - User data indicates a growth in active users by 20% compared to the same period last year, reaching 5 million active users[9]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by the end of 2024[9]. - The company plans to expand its market presence in Southeast Asia, aiming for a 25% market share by 2025[125]. - The company is expanding its market presence, with plans to enter three new provinces by Q4 2023[4]. Product Development and Innovation - New product launches are expected to contribute an additional 200 million yuan in revenue by the end of the year[4]. - A new product line featuring eco-friendly skincare solutions is set to launch in Q3 2023, aiming to capture the growing demand for sustainable products[9]. - The company has developed a brand matrix with 19 categories and 48 product lines, focusing on sensitive skin care products under the "Winona" brand[61]. - The company is focusing on market expansion and new brand development as discussed in the May 18, 2023 roadshow[102]. - The company plans to launch several new products and promotional activities in the second half of 2023 to boost sales and manage inventory effectively[72]. Research and Development - Research and development investments have increased by 30%, focusing on innovative skincare technologies[4]. - Investment in R&D increased by 25% year-on-year, focusing on innovative skincare products and advanced biotechnology[9]. - The company employs over 400 R&D personnel across various disciplines, with core technology sales accounting for over 95% of its main business revenue[63]. - The company has established a comprehensive quality management system that complies with GB/T19001-2016/ISO9001:2015 standards to ensure product safety and quality[64]. - The company emphasizes independent research and development, with a focus on innovative raw materials and collaboration with academic institutions[33]. Financial Management and Investments - The company has no plans to distribute cash dividends or issue bonus shares for this fiscal year[4]. - The company has committed to a share buyback program of up to 100 million CNY to stabilize stock prices[126]. - The total amount of raised funds is RMB 288,389.68 million[84]. - The total cash and cash equivalents at the end of the period were CNY 752,533,865.23, a decrease of 26.4% from CNY 1,021,566,465.17 at the end of the first half of 2022[167]. - The company has a remaining balance of RMB 19,919.46 million in the fundraising special account as of June 30, 2023[86]. Risk Management - The company is actively addressing potential risks, including market competition and regulatory changes, as detailed in the risk management section[4]. - The company faces risks from intensified competition in the cosmetics industry, particularly from international brands increasing their online marketing efforts[96]. - To mitigate risks, the company plans to enhance its strategic adjustments and improve its operational management capabilities[100]. Corporate Governance and Compliance - The company reported a 74.86% investor participation rate at the 2022 annual general meeting held on May 17, 2023[103]. - The company did not experience any major litigation or arbitration matters during the reporting period[133]. - The semi-annual financial report has not been audited[132]. - The company has not conducted any asset or equity acquisitions or sales during the reporting period[135]. Environmental and Social Responsibility - The company has implemented a green supply chain management strategy, creating over 40 quality management documents for the entire product lifecycle[114]. - The company invested over RMB 6.58 million in public welfare projects during the reporting period, benefiting more than 12,600 people through various initiatives[121]. - The "Baiteni Public Welfare Fund" was established to support youth education, biodiversity protection, and rural revitalization, marking its third year of operation[120]. - The company has aligned its biodiversity protection efforts with the COP15 framework, focusing on 23 action goals to fulfill its corporate responsibilities[122]. Supply Chain and Production - The company is enhancing its supply chain efficiency, aiming to reduce production costs by 15% over the next year[9]. - The company has achieved full production capacity for skincare and medical device products, with skincare capacity at approximately 15 million standard units[31]. - The production cost breakdown for skincare products shows that self-produced items account for 19.75%, while commissioned processing constitutes 60.41% of the total[30]. - The company has established a comprehensive supply chain system, ensuring that all suppliers are non-related parties[26]. Marketing and Sales Strategy - The company maintains a multi-channel sales model, with online self-operated sales accounting for a significant portion of revenue through platforms like Tmall and Douyin[25]. - The marketing strategy includes collaboration with KOLs and the use of live streaming and short videos to enhance consumer education and brand awareness[65]. - The company has successfully leveraged internet and AI technologies to enhance its marketing and sales strategies, achieving significant growth in the cosmetics industry[20].

证券代码：300957 证券简称：贝泰妮 公告编号：2023-048 本公司及监事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 云南贝泰妮生物科技集团股份有限公司（以下简称"公司"）第二届监事 会第八次会议于2023年8月28日以现场会议方式在公司会议室举行，现场会议地 点为云南省昆明市高新区科医路 53 号公司会议室。本次会议通知已于2023年8 月18日以邮件方式向全体监事发出。本次会议应出席监事3人，实际出席监事3 人，公司副总经理、财务总监、董事会秘书王龙先生列席会议。本次会议的召 开符合《公司法》及《公司章程》的规定。本次会议由监事会主席余仕汝先生 主持，全体监事审议并表决通过了如下决议： 一、审议通过《关于公司<2023 年半年度报告>全文及摘要的议案》。 公司监事会认为，董事会编制和审核公司《2023年半年度报告》及其摘要 的程序符合法律、法规和中国证监会的规定，报告内容真实、准确、完整地反 映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日刊登于巨潮资讯网的公司《2023年半年度报告》及 其摘要。 表决结果：同意 ...

云南贝泰妮生物科技集团股份有限公司 | | | | | | 2023 年半年 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金 | | 占用方与上 | 上市公司核算 | 年期初占 | 度占用累计 | 2023 年半年 | 2023 年半 | 2023 年半 | 占用形 | | | | 资金占用方名称 | 市公司的关 | | 2023 | 发生金额 | 度占用资金的 | 年度偿还累 | 年末占用资 | | 占用性质 | | 占用 | | 联关系 | 的会计科目 | 用资金余额 | （不含利 | 利息（如有） | 计发生金额 | 金余额 | 成原因 | | | | | | | | 息） | | | | | | | 现大股东及其 | - | - | - | - | - | - | - | - | - | - | | 附属企业 | | | | | | | | | | | | 前大股东及其 | - | - | - | - | - | - | - | - | - | - | | 附属企业 | | ...